This is an excerpt from Wade Pfau's book, Reverse Mortgages: How to Use Reverse Mortgages to Secure Your Retirement

Benefits of a HELOC:
Lower interest rates in most cases
Lower upfront costs
May be more suitable for short term-needs
Benefits of a HECM:
Loan does not become due as long as all the loan obligations are met*
Line of credit cannot be frozen due to changing market values*
No monthly mortgage payments*

Another one of the reverse mortgage advantages over the HELOC is the reliability that the HECM line of credit will stay open and available when needed. HELOCs are notorious for suddenly being decreased or being closed altogether, especially if the borrower has not been actively drawing from the loan. This is difficult because many borrowers prefer to have a line of credit available and open to withdraw from only if the time comes when a need arises. To be forced to stay actively borrowing on the credit line in order to keep an open status or finding out the line of credit has been decreased or closed suddenly would be frustratingly inconvenient for anyone.
The HECM LOC also has an advantage of significant line of credit growth potential. Taking out a HECM early in retirement and keeping the credit line open for use in the future proves to be a popular strategic plan. The unused line of credit grows at current expected interest rates; therefore, taking a HECM at 62 gives your line of credit time to grow as opposed to waiting until 82, especially if the expected reverse mortgage interest rates increase over time.

Where is rono and others who invest in gold ?

livin' from here on out at 32-33, or higher
https://www.multpl.com/shiller-pe

Hopes are soaring that a Covid vaccine is within reach, following news that an interim analysis has shown Pfizer/BioNTech’s candidate was 90% effective in protecting people from transmission of the virus in global trials.
The vaccine performed much better than most experts had hoped for, according to the companies’ analysis, and brings into view a potential end to a pandemic that has killed more than a million people, battered economies and upended daily life worldwide.
The data is from an interim analysis and the trial continues into December but the headline results were emphatic. Regulators will be looking to process an emergency licence application at record speed.
Manufacturing is already under way. Pfizer said they expect to supply globally up to 50m vaccine doses in 2020 and up to 1.3bn doses in 2021. Countries will decide who they prioritise for vaccination.
The news comes too late to help Donald Trump’s re-election campaign in the US, but the vice-president, Mike Pence, tried to claim their administration’s Operation Warp Speed programme had helped the vaccine’s development.
Pfizer denied the suggestion:
“We were never part of the Warp Speed,” Kathrin Jansen, a senior vice-president and the head of vaccine research and development at Pfizer, said in an interview. “We have never taken any money from the US government, or from anyone.”
BioNTech, the small biotechnology company that is the originator of the vaccine, was founded by two married German scientists, Uğur Şahin and Özlem Türeci, both born to Turkish immigrant parents, and the Austrian oncologist Christopher Huber. It originally set out to develop new types of immunotherapy for cancer, but has concentrated its capacities on the race for a Covid-19 vaccine.
There are so far no safety concerns around the vaccine, with the two companies reporting no serious side-effects. The high percentage of those protected makes it especially compelling. Regulators have previously said they would approve a vaccine that has just a 50% effectiveness rate – protecting half of those who get vaccinated.
“We are reaching this critical milestone in our vaccine development programme at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”